CRISPR Therapeutics' drug pipeline revolves around ... published Dec. 20 that it had parted ways with its head of R&D, Tony Ho. Even with the dramatic pullback across the last year of trading ...

In the absence of Lundberg, Tony Ho, M.D., will oversee CRISPR ... that led to the creation of Casebia Therapeutics. Shares in CRISPR exited after-hours trading flat.

The landmark therapy is being co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals for two rare blood disorders. On Tuesday, the Food and Drug Administration (FDA) held an advisory ...

Prior to CRISPR Therapeutics, Dr. Ho was SVP and Head ... is the solid cornerstone of Qihan's product innovation," said Dr. Tony Ho. "I am delighted to join Qihan's Board of Directors, and my ...

Crispr shares are trading higher Thursday after Wolfe Research initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares rise nearly 37% over the past month ...

Crispr Therapeutics CRSP on Tuesday said that Phuong Khanh Morrow was resigning as the gene-editing company’s chief medical officer, a move that takes hold on Jan. 26. The resignation was “not ...

CRISPR Therapeutics AG CRSP shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's CRISPR/Cas9 gene-edited therapy.